Blanchard Cheryl R 4

What Happened
Cheryl R. Blanchard, a director of Xilio Therapeutics (XLO), was granted a derivative award of 10,000 shares (reported as an option) on April 15, 2026. The filing lists an acquisition price of $0.00 (i.e., a grant), and no immediate cash value or exercise price is disclosed in the Form 4. This was a grant of equity compensation, not a purchase or sale of common stock.

Key Details

• Transaction date: April 15, 2026; filing date: April 16, 2026 (timely).
• Security: Derivative (option) for 10,000 shares; reported acquisition price $0.00.
• Vesting: Grants vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to continued service (footnote F1).
• Shares owned after transaction: not specified in the filing.
• Transaction code: A (award/grant). No exercise or sale was reported.

Context
This is a typical director equity grant used for compensation and retention. As a derivative award, the options must vest (per the schedule) and may require exercise (and payment of any strike price, if applicable) before resulting in actual shares; the Form 4 does not disclose a strike or immediate monetary value. Grants are common and do not by themselves indicate an insider buying or selling stock.